OmniAb, Inc. Reports Significant Growth in 2023

March 22, 2024 | by


In the world of biotechnology, OmniAb, Inc. has emerged as a leader in developing innovative therapeutics through its licensing business. This was evident during its Q4 2023 Earnings Conference Call held on March 20, 2024, where the company reported significant growth. With a focus on antibody-based drug discovery, OmniAb offers a suite of cutting-edge technologies, including the newly launched OmniDeep and OmnidAb. This expansion of offerings, along with an increase in active partners, partner programs, and clinical and approved programs, has contributed to the company’s success. Additionally, OmniAb sealed 10 new licensing deals in 2023, solidifying partnerships with both established pharmaceutical giants and emerging start-up companies. Notably, the company experienced multiple successful clinical starts for its partner programs, including collaborations with Seagen, Immunovant, and Cessation. Looking ahead, OmniAb remains committed to continued innovation, with plans for four to six new entries into clinical development in 2024. Its novel transgenic animal technology, OmnidAb, serves as a key differentiating factor for generating highly effective antibodies, solidifying its position as a prominent player in the industry’s growth and advancement.

95paON4hdScokCN81ZxAmvSwy3KpQiLRNGBF4qemM 복사본

Significant Growth in 2023

OmniAb, Inc. (OABI) experienced significant growth in 2023, positioning itself as a leader in innovative therapeutics. The company’s focus on developing novel antibody-based drug discovery technologies through its licensing business has propelled its success. With a strong emphasis on collaboration and partnerships, OmniAb has expanded its partnership base and pipeline, solidifying its position in the industry.

Expansion of Partnership Base

One of OmniAb’s key achievements in 2023 was the expansion of its partnership base. By forging strategic collaborations with both Big Pharma players and start-up companies, OmniAb has been able to leverage a diverse network of partners to drive innovation and maximize its impact. These partnerships have provided access to valuable resources, expertise, and funding, enabling the company to accelerate the development of breakthrough therapeutics.

Screenshot 2024 01 08 192459 1

Expansion of Pipeline

Alongside the expansion of its partnership base, OmniAb experienced significant growth in its pipeline. The company’s pipeline represents a robust portfolio of promising drug candidates across various therapeutic areas. This expansion reflects OmniAb’s commitment to addressing unmet medical needs and leveraging its expertise in antibody discovery and development. With a pipeline that continues to grow and diversify, OmniAb is well-positioned to drive future growth and impact in the biopharmaceutical industry.

Launch of OmniDeep and OmnidAb Technologies

In a testament to its commitment to innovation, OmniAb launched two groundbreaking technologies in 2023: OmniDeep and OmnidAb. These technologies further enhance the company’s antibody-based drug discovery capabilities, allowing for the generation of high-quality monoclonal antibodies with enhanced therapeutic potential. OmniDeep leverages advanced computational algorithms to streamline antibody discovery, while OmnidAb represents a novel transgenic animal technology that significantly accelerates the generation of antibodies with human-like properties. These technologies have positioned OmniAb as a leader in antibody discovery and have opened up new opportunities for therapeutic development.

Growth in Active Partners

Another notable achievement for OmniAb in 2023 was its growth in active partners. The company’s commitment to fostering strong and collaborative relationships with its partners has resulted in an expanded network of active collaborators. The value of these partnerships extends beyond financial support, as they provide access to critical expertise and diverse perspectives. OmniAb’s growing network of active partners serves as a testament to the company’s ability to attract and retain industry-leading collaborators who share its vision of advancing therapeutics for the benefit of patients.

Growth in Active Partner Programs

In parallel with the growth of active partners, OmniAb has also seen a significant increase in active partner programs. These programs represent collaborative efforts between OmniAb and its partners to develop novel therapeutic candidates using OmniAb’s innovative technologies. With a growing number of active partner programs, OmniAb is able to combine its expertise in antibody discovery with the unique insights and resources of its partners, fostering a synergistic approach to drug development. This growth in active partner programs highlights the efficacy and value of OmniAb’s collaborative model.

Growth in Active Clinical and Approved Programs

OmniAb’s commitment to advancing therapeutics is reflected in the growth of its active clinical and approved programs. The company has made substantial progress in advancing the development of its partnered programs through clinical trials and regulatory approvals. Successful clinical starts for partner programs with renowned companies such as Seagen, Immunovant, and Cessation have demonstrated the effectiveness of OmniAb’s technologies in translating scientific discoveries into potential breakthrough therapies. With an increasing number of active clinical and approved programs, OmniAb is poised to make a significant impact on patient care and bring life-changing therapies to the market.

Signing of 10 New Licensing Deals

In 2023, OmniAb further expanded its licensing business by signing 10 new licensing deals. These deals encompassed partnerships with both established pharmaceutical companies and emerging biotech firms, solidifying OmniAb’s position as a preferred partner for antibody-based drug discovery. The successful collaborations with industry leaders and innovative start-ups are a testament to the quality and potential of OmniAb’s technology platform. These licensing deals not only provide financial benefits but also foster knowledge sharing and cross-pollination of ideas, further strengthening OmniAb’s position as an industry pioneer.


Successful Clinical Starts for Partner Programs

Among OmniAb’s notable achievements in 2023 were the successful clinical starts for its partner programs. Collaborations with Seagen, Immunovant, Cessation, and other renowned companies have generated significant momentum in advancing therapeutic candidates through the clinical trial process. The achievements exemplify OmniAb’s ability to effectively partner with industry leaders and drive successful clinical development. These milestones represent a validation of OmniAb’s technology platform and its potential to revolutionize the field of antibody-based therapeutics.

Commitment to Continued Innovation

OmniAb’s commitment to continued innovation remains unwavering. The company recognizes the importance of staying at the forefront of scientific advancements and is dedicated to pushing the boundaries of antibody discovery and development. By investing in research and development, OmniAb aims to continually enhance its technology platform and expand its capabilities. This commitment to innovation ensures that OmniAb remains well-positioned to address evolving medical needs and drive meaningful progress in the biopharmaceutical industry.

Anticipation of New Entries into Clinical Development in 2024

Looking ahead, OmniAb anticipates the entry of four to six new programs into clinical development in 2024. These new additions to the company’s clinical pipeline represent the fruition of its collaborative efforts with partners and the continuous advancement of its technology platform. With a strong track record in successful clinical starts, OmniAb is optimistic about the potential of these new programs to deliver transformative therapies. The anticipation of new entries into clinical development underscores OmniAb’s confidence in its ability to consistently innovate and bring cutting-edge therapeutics to patients in need.

In conclusion, OmniAb, Inc. experienced significant growth in 2023, fueled by the expansion of its partnership base, pipeline, and the launch of innovative technologies. The company’s achievements in growing its active partners, partner programs, and clinical and approved programs are a testament to its collaborative approach and focus on advancing therapeutics. With successful clinical starts, new licensing deals, and a commitment to continued innovation, OmniAb is well-positioned for further growth and impact in the biopharmaceutical industry. Anticipation of new entries into clinical development in 2024 further reinforces OmniAb’s dedication to advancing novel therapeutics for the benefit of patients worldwide.

420975661 930960805057803 3457597750388070468 n


View all

view all